Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports
- PMID: 11769824
- DOI: 10.1177/026988110101500408
Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports
Abstract
Hyperprolactinaemia is a common side-effect of many antipsychotic drugs but, in comparison to extrapyramidal side-effects, it has received little attention. Four case reports are presented which illustrate important clinical and pharmacological aspects of the syndrome. Two of the cases were caused by conventional antipsychotic drugs and two by risperidone, an atypical antipsychotic. Symptoms included gynaecomastia, galactorrhoea, amenorrhoea and sexual dysfunction. Three patients were switched to a prolactin sparing antipsychotic leading to normalization of serum prolactin and resolution of the symptoms. Patients prescribed prolactin elevating antipsychotics should, where possible, have this issue explained to them prior to commencing treatment and be screened for symptoms suggestive of hyperprolactinaemia before starting treatment and regularly thereafter.
Similar articles
-
Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.Drugs. 2004;64(20):2291-314. doi: 10.2165/00003495-200464200-00003. Drugs. 2004. PMID: 15456328 Review.
-
Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.J Psychopharmacol. 2012 May;26(5 Suppl):42-51. doi: 10.1177/0269881112442016. Epub 2012 Apr 2. J Psychopharmacol. 2012. PMID: 22472310 Review.
-
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.J Psychopharmacol. 2007 Sep;21(7):768-73. doi: 10.1177/0269881107078281. Epub 2007 Jul 2. J Psychopharmacol. 2007. PMID: 17606473
-
Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.J Psychopharmacol. 2012 Feb;26(2):324-9. doi: 10.1177/0269881110393051. Epub 2011 Jan 24. J Psychopharmacol. 2012. PMID: 21262859
-
Prolactin awareness: an essential consideration for physical health in schizophrenia.Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Eur Neuropsychopharmacol. 2008. PMID: 18346598 Review.
Cited by
-
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.Psychiatr Q. 2013 Mar;84(1):125-35. doi: 10.1007/s11126-012-9233-3. Psychiatr Q. 2013. PMID: 22806578
-
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.Patient Relat Outcome Meas. 2014 Jun 23;5:43-62. doi: 10.2147/PROM.S42735. eCollection 2014. Patient Relat Outcome Meas. 2014. PMID: 25061342 Free PMC article. Review.
-
Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.Drugs. 2004;64(20):2291-314. doi: 10.2165/00003495-200464200-00003. Drugs. 2004. PMID: 15456328 Review.
-
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).BMC Psychiatry. 2013 Aug 22;13:214. doi: 10.1186/1471-244X-13-214. BMC Psychiatry. 2013. PMID: 23968123 Free PMC article. Clinical Trial.
-
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.CNS Drugs. 2021 May;35(5):507-526. doi: 10.1007/s40263-021-00812-1. Epub 2021 Apr 20. CNS Drugs. 2021. PMID: 33880739 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources